EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions

Benzinga_recent_news10-01

Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Wednesday the formalization of multiple commercial group purchasing organization (GPO) agreements for its new drug, Arbli (losartan potassium) Oral ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2572531055?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/01/Pulmonary-Hypertension-Medicine-Doctor-H.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-10-01 20:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572531055","market":"us","top_or_hot":-1,"title":"EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions","media":"Benzinga_recent_news","content":"<div>\n<p>Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Wednesday the formalization of multiple commercial group purchasing organization (GPO) agreements for its new drug, Arbli (losartan potassium) Oral ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/10/47966068/exclusive-scienture-secures-purchase-agreements-healthcare-institutions\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-01 20:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/25/10/47966068/exclusive-scienture-secures-purchase-agreements-healthcare-institutions><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Wednesday the formalization of multiple commercial group purchasing organization (GPO) agreements for its new drug, Arbli (losartan potassium) Oral ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/10/47966068/exclusive-scienture-secures-purchase-agreements-healthcare-institutions\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HCSG","symbol_name":"Healthcare Svcs Group Inc","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/10/47966068/exclusive-scienture-secures-purchase-agreements-healthcare-institutions","article_id":"2572531055","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/01/Pulmonary-Hypertension-Medicine-Doctor-H.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/10/47966068/exclusive-scienture-secures-purchase-agreements-healthcare-institutions","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2572531055","pubTimestamp":1759322760,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Scienture Holdings, Inc. announced GPO agreements for its new drug, Arbli, providing access to over 2,500 healthcare institutions and plans to expand further.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HCSG":"Healthcare Svcs Group Inc","BK4137":"综合支持服务","SCNX":"Scienture Holdings, Inc.","XLV":"健康照护类股ETF-SPDR","BK4581":"高盛持仓","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LABU":"三倍做多标普生物-Direxion","BK4167":"医疗保健技术","PBM":"Psyence Biomedical Ltd","XBI":"SPDR S&P Biotech ETF"},"translate_title":"独家：Scienture与2,500家医疗机构签订高血压药物采购协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":0.6,"LABU":0.6,"HCSG":1.5,"SCNX":1,"XLV":1.5,"PBM":1},"content_text":"Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Wednesday the formalization of multiple commercial group purchasing organization (GPO) agreements for its new drug, Arbli (losartan potassium) Oral Suspension, 10 mg/mL.\nThe agreements will provide the company access to more than 2,500 healthcare institutions across the U.S., including hospitals, clinics, and long-term care facilities.\nThe company stated that the deal represents a significant step for them as they seek to penetrate an estimated 20% of the U.S. institutional market with their novel liquid formulation of a widely prescribed hypertension medication.\nAlso Read: Medicare Beneficiaries To See Slight Premium Decline Next Year\nTwo weeks ago, Scienture formalized a commercial Pharmacy Benefit Manager (PBM)- led Group Purchasing Organization (GPO) rebate agreement, advancing the process of securing formulary access with health plans that cover more than 100 million lives.\nArbli is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes.\nArbli is the first and only FDA-approved, ready-to-use oral liquid losartan available in the U.S.\n“By gaining access to more than 2,500 healthcare institutions, we are positioning Arbli to reach the patients and providers who need it most,” said Narasimhan Mani, president and co-CEO of Scienture.\nArbli is the first and only liquid formulation of losartan on the market that does not require compounding, offering reduced dosing volume and a long-term shelf life at room temperature storage.\nArbli has two issued patents from the USPTO, which are also listed in the FDA Orangebook.\nAccording to IQVIA data (MAT June 2025), the U.S. losartan market represents approximately $256 million in annual sales and a prescription volume of 71 million (TRx), with all currently marketed products available only in oral solid form.\nIn August, Scienture announced a registered direct offering of 3.225 million shares at $1.20 per share, with gross proceeds of approximately $3.9 million.\nSCNX Price Action: Scienture Holdings shares were down 0.16% at $0.84 during premarket trading on Wednesday. The stock is trading near its 52-week low of $0.69, according to Benzinga Pro data.\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2572531055","isCrawlerRequest":true}